Update on AUA guideline on the management of XXXX .

@entity1 @entity1067 @entity5450
PURPOSE: To revise the 2003 version of the American Urological Association's (AUA) Guideline on the management of @entity1067 ( @entity1067 ). MATERIALS AND METHODS: From MEDLINE   searches of English language publications (January 1999 through February 2008) using relevant MeSH terms, articles concerning the management of the index @entity1 , a male >= 45 years of age who is consulting a healthcare provider for lower urinary tract symptoms (LUTS) were identified. Qualitative analysis of the evidence was performed. Selected studies were stratified by design, comparator, follow-up interval, and intensity of intervention, and meta-analyses (quantitative synthesis) of outcomes of randomized controlled trials were planned. Guideline statements were drafted by an appointed expert Panel based on the evidence. RESULTS: The studies varied as to @entity1 selection; randomization; blinding mechanism; run-in periods; @entity1 demographics, comorbidities, prostate characteristics and symptoms; drug doses; other intervention characteristics; comparators; rigor and intervals of follow-up; trial duration and timing; suspected lack of applicability to current US practice; and techniques of outcomes measurement. These variations affected the quality of the evidence reviewed making formal meta-analysis impractical or futile. Instead, the Panel and extractors reviewed the data in a systematic fashion and without statistical rigor. Diagnosis and treatment algorithms were adopted from the 2005 International Consultation of @entity5450 . Guideline statements concerning pharmacotherapies, watchful waiting, surgical options and minimally invasive procedures were either updated or newly drafted, peer reviewed and approved by AUA Board of Directors. CONCLUSIONS: New pharmacotherapies and technologies have emerged which have impacted treatment algorithms. The management of LUTS/ @entity1067 continues to evolve.
